Phillip M Hughes1,2, Genevieve Verrastro3, Carriedelle Wilson Fusco3, Courtenay Gilmore Wilson1,3,4,5, Bayla Ostrach1. 1. Department of Research, UNC Health Sciences at MAHEC, Asheville, North Carolina, USA. 2. Division of Pharmaceutical Outcomes and Policy, University of North Carolina (UNC) Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA. 3. Department of Family Medicine, Mountain Area Health Education Center (MAHEC), Asheville, North Carolina, USA. 4. Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA. 5. Charles George Veterans Affairs Medical Center, Asheville, North Carolina, USA.
Abstract
PURPOSE: Tracking changes in care utilization of medication for opioid use disorder (MOUD) services before, during, and after COVID-19-associated changes in policy and service delivery in a mixed rural and micropolitan setting. METHODS: Using a retrospective, open-cohort design, we examined visit data of MOUD patients at a family medicine clinic across three identified periods: pre-COVID, COVID transition, and COVID. Outcome measures include the number and type of visits (in-person or telehealth), the number of new patients entering treatment, and the number of urine drug screens performed. Distance from patient residence to clinic was calculated to assess access to care in rural areas. Goodness-of-Fit Chi-Square tests and ANOVAs were used to identify differences between time periods. FINDINGS: Total MOUD visits increased during COVID (436 pre vs. 581 post, p < 0.001), while overall new patient visits remained constant (33 pre vs. 29 post, p = 0.755). The clinic's overall catchment area increased in size, with new patients coming primarily from rural areas. Length of time between urine drug screens increased (21.1 days pre vs. 43.5 days post, p < 0.001). CONCLUSIONS: The patterns of MOUD care utilization during this period demonstrate the effectiveness of telehealth in this area. Policy changes allowing for MOUD to be delivered via telehealth, waiving the need for in-person initiation of MOUD, and increased Medicaid compensation for MOUD may play a valuable role in improving access to MOUD during the COVID-19 pandemic and beyond.
PURPOSE: Tracking changes in care utilization of medication for opioid use disorder (MOUD) services before, during, and after COVID-19-associated changes in policy and service delivery in a mixed rural and micropolitan setting. METHODS: Using a retrospective, open-cohort design, we examined visit data of MOUD patients at a family medicine clinic across three identified periods: pre-COVID, COVID transition, and COVID. Outcome measures include the number and type of visits (in-person or telehealth), the number of new patients entering treatment, and the number of urine drug screens performed. Distance from patient residence to clinic was calculated to assess access to care in rural areas. Goodness-of-Fit Chi-Square tests and ANOVAs were used to identify differences between time periods. FINDINGS: Total MOUD visits increased during COVID (436 pre vs. 581 post, p < 0.001), while overall new patient visits remained constant (33 pre vs. 29 post, p = 0.755). The clinic's overall catchment area increased in size, with new patients coming primarily from rural areas. Length of time between urine drug screens increased (21.1 days pre vs. 43.5 days post, p < 0.001). CONCLUSIONS: The patterns of MOUD care utilization during this period demonstrate the effectiveness of telehealth in this area. Policy changes allowing for MOUD to be delivered via telehealth, waiving the need for in-person initiation of MOUD, and increased Medicaid compensation for MOUD may play a valuable role in improving access to MOUD during the COVID-19 pandemic and beyond.
Authors: Rebecca S Bolinski; Suzan Walters; Elizabeth Salisbury-Afshar; Lawrence J Ouellet; Wiley D Jenkins; Ellen Almirol; Brent Van Ham; Scott Fletcher; Christian Johnson; John A Schneider; Danielle Ompad; Mai T Pho Journal: Int J Environ Res Public Health Date: 2022-02-16 Impact factor: 3.390
Authors: Jennifer M Ludrosky; Amanda Newhouse; Erin Hudnall; Ashley Sheree; Jonathan G Perle Journal: J Behav Health Serv Res Date: 2022-08-09 Impact factor: 1.475
Authors: Anh Truc Vo; Thomas Patton; Amy Peacock; Sarah Larney; Annick Borquez Journal: Int J Environ Res Public Health Date: 2022-07-21 Impact factor: 4.614